US FDA Advisory Committee endorses the effectiveness and safety of single-dose tafenoquine for the radical cure of P. vivax malaria
(WorldNews Health)

Issued: London UK; Philadelphia US; Geneva, Switzerland GSK and Medicines for Malaria Venture (MMV) today announced that the Antimicrobial Drugs Advisory Committee (AMDAC) of the United States Food and Drug Administration (FDA) voted that there is substantial evidence of the effectiveness (13 for; 0 against) and adequate evidence of the safety (12 for; 1 against) of single-dose tafenoquine for the radical cure (prevention of relapse) of Plasmodium vivax (P. vivax)malaria in patients 16 years of age and older. Pauline Williams, Head of Global Health R&D, GSK said: `After extensive efforts to develop a new treatment for patients with P. vivax malaria, working in collaboration with Medicines...